Onderneming Evotec SE Other OTC
Aandelen
EVTCY
US30050E1055
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
EVT Execute
65,8
%
| 547 | 72,8 % | 515 | 65,8 % | -5,89% |
EVT Innovate
34,2
%
| 205 | 27,2 % | 267 | 34,2 % | +30,36% |
Verkoop per regio
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
59,5
%
| 418 | 55,7 % | 459 | 59,5 % | +9,83% |
Rest of the World
12,3
%
| 127 | 16,9 % | 95 | 12,3 % | -24,91% |
United Kingdom
11,2
%
| 115 | 15,3 % | 86 | 11,2 % | -25,06% |
Switzerland
8,4
%
| - | - | 65 | 8,4 % | - |
Germany
4,4
%
| 59 | 7,8 % | 34 | 4,4 % | -42,04% |
France
4,1
%
| 32 | 4,3 % | 32 | 4,1 % | -0,83% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19-06-19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 07-02-23 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 01-05-12 |
Cord Dohrmann
CTO | Chief Tech/Sci/R&D Officer | 60 | 01-09-10 |
Gabriele Hansen
IRO | Public Communications Contact | - | - |
Volker Braun
IRC | Investor Relations Contact | - | - |
Matthias Evers
PRN | Corporate Officer/Principal | 51 | 01-05-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19-06-19 |
Roland Sackers
BRD | Director/Board Member | 56 | 19-06-19 |
Chairman | 63 | 17-06-14 | |
Director/Board Member | 41 | 22-06-22 | |
Director/Board Member | 62 | 01-06-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 177 542 097 | 160 931 634 ( 90,64 %) | 249 915 ( 0,1408 %) | 90,64 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
EXSCIENTIA PLC 11.86% | 14 035 200 | 11.86% | 74 386 560 $ |
Bedrijfsgegevens
![Adres Evotec SE(EVTCY)](https://cdn.zonebourse.com/static/address/3021168.png)
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Evotec (France) SAS
![]() Evotec (France) SAS Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (France) SAS is a French company that engages in research and development of physical and natural sciences. The company is based in Toulouse, France. The company was founded in 2014. Pierre Cooremans has been the CEO of the company since 2019. |
Miscellaneous Commercial Services
|
Evotec (UK) Ltd.
![]() Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991. |
Miscellaneous Commercial Services
|
Evotec International GmbH
![]() Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany. |
Miscellaneous Commercial Services
|
Aptuit (Verona) Srl
![]() Aptuit (Verona) Srl Pharmaceuticals: MajorHealth Technology Aptuit (Verona) Srl engages in the provision of integrated drug development solutions. It offers Indigo and Indigo-Select. The company was founded in 2004 and is headquartered in Verona, Italy. |
Pharmaceuticals: Major
|
Sector
Verkoop per activiteit
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,80% | 53,67 mld. | |
+35,79% | 38,86 mld. | |
-8,05% | 38,76 mld. | |
-8,98% | 27,27 mld. | |
+10,69% | 25,91 mld. | |
-16,21% | 20,29 mld. | |
+31,00% | 12,78 mld. | |
+28,51% | 12,18 mld. | |
-1,67% | 11,96 mld. |